Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity
University of California, San Francisco · Czech Academy of Sciences · +4 more institutions
Abstract
The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome proliferator-activated receptor-gamma (PPARgamma) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARgamma have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes. Here we report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARgamma; influence the expression of PPARgamma target…
Citation impact
- FWCI
- 25.79
- Percentile
- 100%
- References
- 72
Authors
10- SCStephen C. BensonCorresponding
University of California, San Francisco, Czech Academy of Sciences, University of California, Irvine, Kern Medical Center, University of Mississippi, Czech Academy of Sciences, Institute of Physiology
- HAHarrihar A. Pershadsingh
University of California, San Francisco, Czech Academy of Sciences, University of California, Irvine, Kern Medical Center, University of Mississippi, Czech Academy of Sciences, Institute of Physiology
- CHChristopher Ho
University of California, San Francisco, Czech Academy of Sciences, University of California, Irvine, Kern Medical Center, University of Mississippi, Czech Academy of Sciences, Institute of Physiology
- AGAmar G. Chittiboyina
University of California, San Francisco, Czech Academy of Sciences, University of California, Irvine, Kern Medical Center, University of Mississippi, Czech Academy of Sciences, Institute of Physiology
- PDPrashant Desai
University of California, San Francisco, Czech Academy of Sciences, University of California, Irvine, Kern Medical Center, University of Mississippi, Czech Academy of Sciences, Institute of Physiology
Topics & keywords
- Telmisartan
- Endocrinology
- Insulin resistance
- Internal medicine
- Angiotensin II
- Diabetes mellitus
- Metabolic syndrome
- Peroxisome proliferator-activated receptor
- Good health and well-being